CNTX
Guggenheim gives a Buy recommendation for Context Therapeutics Inc (CNTX)
Daniel Torres
Context Therapeutics Inc’s recently made public that its Chief Executive Officer Lehr Martin A. acquired Company’s shares for reported $70080.0 ...
Analysts review Context Therapeutics Inc’s rating
Anna Perez
Context Therapeutics Inc’s recent filing unveils that its Chief Executive Officer Lehr Martin A. acquired Company’s shares for reported $70080.0 ...
CNTX’s short interest reaches 0.69 million shares on 2025-11-14
Daniel Torres
The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or ...
0 analysts rank CNTX stock as an Overweight
Roman Campbell
Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Context Therapeutics ...
Examining the Potential Price Growth of Context Therapeutics Inc (CNTX)
Daniel Torres
Context Therapeutics Inc’s filing revealed that its Chief Executive Officer Lehr Martin A. acquired Company’s shares for reported $70080.0 on ...
